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Comparison the Effect of Letrozole Versus Medroxy 
Progesterone Acetate on Premenopausal Patients With 
Endometrial Hyperplasia: An Randomized clinical trial
Introduction
An abnormal bleeding which occurs in an unlimited time 
of the menstrual cycle is called abnormal uterine bleeding. 
This type of bleeding needs to be investigated in all ages, 
especially before menopause. After ruling out the organ-
ic causes, the most common cause of abnormal uterine 
bleeding is anovulation and subsequently, the endome-
trial hyperplasia (1,2). The term endometrial hyperplasia 
explains the spectrum of combined effects of endometrial 
glands and stroma, and these conditions are usually ob-
served during the investigation of abnormal bleeding and 
its frequent treatment (3,4). The irregular bleeding leads to 
some problems such as anemia, marital problems, infertil-
ity, and an increased risk of endometrial cancer; therefore, 
patients should follow the duration of their treatment se-
riously due to the fear of cancer. Endometrial hyperplasia 
is an estrogen-dependent disease caused by internal and 
external hormones (3,5).
Hyperplasia is usually caused by the proliferative en-
dometrium and long stimulation of estrogen in the ab-
sence of progestin (6). This disease has 2 kinds, which are 
known as simple and complex kinds, and each of them can 
exist with atypia or without atypia. The risk of progression 
towards cancer in simple and complex hyperplasia is 1% 
and 3%, respectively. Moreover, the simple and complex 
hyperplasia with atypia (presence of nuclear enlargement, 
the chromatin may be either evenly dispersed or clumped) 
increases the risk of cancer progression up to 8% and 29%, 
respectively (7). 
The significance of all kinds of hyperplasia diseases is 
due to the fact that they cause the abnormal bleeding, and 
they occur before cancer or simultaneously with cancer 
(7).
Estrogen is one of the important hormones present in 
the body of women, and is secreted by the ovaries before 
menopause (6). One of the most common and important 
factors that determines the progress of endometrial hy-
perplasia is overweight which results in endometrial can-
cer. Endogen changes into estrogen by aromatase in pe-
ripheral tissues; this enzyme is stored in the adipose tissue.
Anti-estrogen drugs like progesterone and gonadotro-
pin-releasing hormone agonists cause endometrial hy-
perplasia to reoccur (1,8). Medroxyprogesterone acetate 
is typically first line therapy for non-atypical endometrial 
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hyperplasia but, these drugs have some complications. 
Various reports have shown some side effects such as ad-
verse cardiovascular effects, increasing the load of lipids 
and lipoproteins, overweight, and mood changes due to 
consumption of progesterone (7). Treatment with gonad-
otropin-releasing hormone agonist results in osteoporosis 
and vasomotor effects (9-11).
Among other drugs that have been recently discussed 
for hyperplasia treatment, are aromatase inhibitors like 
letrozole and anastrozole that inhibit the aromatization 
of endogen into estrogen. Letrozole is a triazole deriva-
tive that is potent, reversible, competitive, nonsteroidal 
aromatase inhibitor. Letrozole cannot reduce the number 
of estrogen receptors. It can inhibit estrogen biosynthe-
sis by 97% to 99%, resulting in estrogen concentrations 
below the level detected by most sensitive immunoassays. 
They are completely absorbed after oral administration 
and have a mean terminal half life of approximately 45 
hours, clearance is mainly hepatic. This drug is useful in 
advanced breast cancer treatment as an adjuvant therapy. 
More recently, this medicine was used as a stimulant for 
women with child-bearing problem (7). In many studies, 
its complications are lower than other applied drugs for 
medical treatment of hyperplasia (8,12).
The aim of this study is to obtain medication for the 
treatment of endometrial hyperplasia with fewer side ef-
fects. Then we compared 2 applied medicines for hyper-
plasia treatment (medroxyprogesterone and letrozole) in 
patients with endometrial hyperplasia who were referred 
to the Abolfazle Health Clinic.
Material and Methods
This research is a randomized clinical trial (Trial Regis-
tration: irct.ir, Identifier: IRCT201510244339N12), con-
ducted using a table of random numbers, after obtaining 
approval from the ethics committee and informed consent 
of participants. 
At first, a vaginal ultrasound (Honda, 2100, Japan) was 
done by an experienced gynecologist on patients with ab-
normal bleeding, who were referred to Abolfazle clinic in 
Bushehr at the beginning of 2011 till late 2014. Endome-
trial thickness was estimated between 2 wide pints in the 
area of hyperechogenic in a vertical cut of the sagittal axis 
of the uterus. Inclusion criteria in the study consist of re-
productive age women, lack of pregnancy and existence of 
simple endometrial hyperplasia in the pathology report. 
The exclusion criteria in this research include non-re-
productive ages, pregnancy, and existence of complex 
hyperplasia with atypia in pathology report, liver disease, 
existence of fibroids in uterus and existence of cyst in the 
ovaries. 
When the endometrial thickness was more 12 mm, the 
curettage surgery was performed in the operating room 
for the referent patient, and the obtained sample was ana-
lyzed in the hospital’s laboratory by 2 pathologists; there-
fore, patients with simple hyperplasia were studied in this 
research. After performing the curettage surgery and sim-
ple endometrial hyperplasia approval, at first, the level of 
blood estradiol was measured during the second and third 
day of menstruation, and then the patients were classified 
into two 40-person groups, based on the table of random 
numbers in Excel program. The first group was given a 5 
mg medroxyprogesterone acetate tablet (Hormone Com-
pany, Iran). On the 16th day of menstruation, every night, 
2 tablets were given 14 nights in each month for 3 months, 
and the second group was given 2.5 mg letrozole tablet 
(Hormone Company, Iran) continuously for 3 months. At 
the end of each month, the patients were visited regarding 
their menstruation condition and side effects, and all the 
data were recorded in the questionnaire. At the end of the 
third and sixth months, vaginal ultrasound was performed 
again for the patients, in order to analyze the endometrial 
thickness, and the blood’s estradiol was measured again. 
In addition, endometrial biopsy was done, and pathology’s 
report was followed. 
Statistical Analyses 
Statistical analysis was performed by the Statistical Pack-
age for Social Science (SPSS) version 11.5 for Windows 
(SPSS Inc., Chicago, IL, USA). The data was analyzed by 
student’s t test, chi-squared test and t test for linear trend 
and proportions were compared. A P value of < 0.05 was 
considered to be statistically significant. 
Results
In 2 case-study groups, 80 patients enrolled (40 patients in 
letrozole group and 40 patients in medroxyprogesterone 
group). There were no significant differences in the base 
variables. Age average in the group treated with medroxy-
progesterone (group A) and the other group treated with 
letrozole (group B) was 36.15 ± 4.55 years and 37.15 ± 
6.96 years, respectively (P = 0.449), and the difference was 
not significant. The body mass index (BMI) for groups A 
and B was 27.01± 4.97 kg/m2 and 25.43 ±4.81 kg/m2, re-
spectively (P = 0.104). Thus, it indicates that there was no 
significant difference between the 2 groups. The level of 
estradiol in groups A and B before treatment was 52.6 ± 
23.88 pg/mL and 62.98 ± 36.56 pg/mL (P = 0.139) which 
was similar in the 2 groups. Moreover, endometrial thick-
ness in groups A and B was 15.60 ± 3.34 and 14.61 ± 3.83 
mm, respectively (P = 0.222), and this difference was not 
statistically significant (Table 1). 
In the letrozole-received group, the level of endometrial 
thickness before the treatment was 14.61 ± 3.83 mm and it 
reached 10.72 ± 3.65 mm after treatment. Moreover, this 
amount in medroxyprogesterone group was 15.60 ± 3.34 
mm and it was 11.55 ± 5.78 mm after treatment. The dif-
ference between these 2 groups from the endometrial 
thickness reduction viewpoint is significant (P < 0.0001). 
The level of estradiol in serum in the letrozole group was 
62.98 ± 36.56 pg/mL before treatment, and it reached 29.67 
± 23.69 pg/mL after treatment (P = 0.0001). This decline 
was significant, and in medroxyprogesterone group, it was 
52.6 ± 23.88 pg/mL before treatment and 32.10 ± 17.30 pg/
mL after treatment (P = 0.0001); thus, this difference is sig-
nificant. Reduction percentage of the level of estradiol in 
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serum in the medroxyprogesterone and letrozole groups 
is 37% and 42%, respectively (P = 0.602), and the differ-
ence is not significant (Tables 2 and 3). There was not any 
significant correlation between endometrial thickness and 
serum level of estradiol in both groups after intervention 
(P > 0.05).
In terms of comparing the menstrual status between the 
2 groups and different stages of treatment, about 80%-90% 
of the patients had normal menstruation in the letrozole 
group and 65%-70% had normal menstruation in the 
medroxyprogesterone group. There was no significant 
difference between these 2 groups from the menstrual sta-
tus standpoint between 2, 3 and 6 months after treatment. 
However, this difference was significant between before 
and after the treatment in each group, since all patients 
had hyper menorrhea (Table 4).
Discussion
The present study shows that there was no difference be-
tween endometrial thickness reduction after treatment 
with letrozole and medroxyprogesterone in childbear-
ing-age women and hyperplasia without atypia, and their 
menstrual status was better than before the treatment.
Moreover, the study indicates reduction of serum estra-
diol level in the group given letrozole. This is not signifi-
cantly more than reduction of serum estradiol level in the 
group which received medroxyprogesterone acetate. 
This research shows that letrozole can be used to treat 
patients with simple hyperplasia, and they cannot undergo 
treatment with medroxyprogesterone, if they are sensitive 
to it and produce complications (like mood changes, and 
vascular and metabolic changes). In overweight patients 
with high level of estrogen (due to the storage of estrogen 
in adipose tissue) and in women who are in the late child-
bearing ages, there is the risk of other cancers like breast 
cancer. Therefore, they can use aromatase inhibitor as a 
complementary therapy, and it is also used for patients 
who have estrogen-secreting ovarian tumor. 
A research was conducted by EL-Shamy et al on women 
with simple hyperplasia without atypia in which 2 groups 
were given letrozole and medroxyprogesterone, and at the 
end of the research, they mentioned that there was no sig-
nificant and clear difference among the resistant, progres-
sive and hyperplasia groups. Endometrial thickness was 
significantly reduced in patients who received letrozole as 
compared to those who received progesterone (1).
There was no significant difference between the pres-
ent study and this research in the 2 groups, with regards 
to the endometrial thickness, and unlike this study, the 
present research showed that consuming letrozole and 
progesterone resulted in a decrease in endometrial thick-
ness. However, similar to this study, the use of letrozole 
has significantly decreased the level of estradiol in serum 
as compared to progesterone. In a research conducted in 
2012, the effect of progesterone and letrozole on endome-
trial thickness atrophy was equal in simple endometrial 
hyperplasia (1).
According to a research carried out by Baruah et al, 
endometrial thickness was analyzed regarding the com-
parison of letrozole and clomiphene citrate, and resistance 
and pulsate indexes were measured in spiral arteries of the 
Table 1. Demographic of Patients in 2 Groups
Variable
Group A  
Mean ± SD
Group B 
Mean ± SD
P
Age (y) 36.15±4.55 37.15±6.96 0.449a
BMI (kg/m2) 27.01±4.97 25.43±4.81 0.152a
Estradiol level before 
treatment (pg/mL)
52.6±23.88 62.98±36.56 0.139b
Endometrial thickness 
(mm)
15.60±3.34 14.61±3.83 0.222a
a Independent t test;  b Mann-Whitney test.
Table 2.  Comparison Between Endometrial Thickness and Estradiol 
Level Before and After Treatment in 2 Groups
Variable Group A Group B P
Estradiol level after  
treatment (pg/mL)
32.10±17.30 29.67±23.69 0.602a
Endometrial thickness 
after treatment (mm)
11.55±5.78 10.72±3.65 0.445b
a Mann-Whitney test; b Independent t test.
Table 3. Level of Decline in Estradiol and Endometrial Thickness After Treatment in 2 Groups
Group Treatment
Decline in Estradiol Level After Treatment Decline in Endometrial Thickness After Treatment
Mean ± SD P Value * Mean ± SD P Valuea
A 20.49±16.04 <0.0001 4.05±6.64 <0.0001
B 33.31±16.04 <0.0001 3.89±4.55 <0.0001
a Independent t test.
Table 4. Menstruation in 2 Groups After Treatment
Duration of Treatment
Group A Group B
P ValueaNormal
No. (%)
Hypermenorrhea
No. (%)
Normal
No. (%)
Hypermenorrhea
No. (%)
Two months after treatment 28 (70) 12 (30) 32 (80) 8 (20) 0.439
Three months after treatment 27(67.5) 13 (32.5) 34 (85) 6 (15) 0.115
Six months after treatment 28(70) 12 (30) 32 (80) 8 (20) 0.439
a Chi square test.
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uterus by Doppler ultrasound, and it indicated that there 
was less vascular resistance; therefore, it affects endome-
trial thickness more and better than clomiphene citrate 
(13). The difference between our study and this research 
is that the compared group in this research is clomiphene, 
although at the end of the research, the endometrial thick-
ness decreased like in our study.
Barker et al conducted a study on sixteen women, hav-
ing a BMI of 34.5 in the post-menopausal period, and 
they had endometrial carcinoma and simple hyperplasia; 
therefore, they were treated with letrozole. As a result, the 
patients’ endometrial thickness was decreased, but there 
was no response and inference for the four patients with 
metastatic disease (14).
This study differs from our research in which the aver-
age amount of BMI for this research patients was 34.5 and 
it indicates that these patients are overweight as compared 
to the our study with an average BMI = 28±4 in medroxy-
progesterone group and BMI = 25±4 in letrozole group. 
However, as the number of people present in each group 
of BMI was low, this relationship could not be determined. 
This study was done on post-menopausal women, where-
as our study was on women of reproductive-age, and the 
duration of treatment in this study was 36 months; in 
addition, endometrial thickness was decreased to about 
81.7% (14.7 to 2.7 mm). The endometrial thickness in our 
study decreased from 14.6 to 10.7 mm. In a research per-
formed by Li et al in 2008, letrozole was prescribed for 5 
women with in childbearing age, which had endometrial 
hyperplasia. At the end of the research, reduction of se-
rum estradiol level and recovery from hyperplasia was ob-
served (8). Also in this research, both reduction of serum 
estradiol and reduction of endometrial thickness were ob-
served after a 3-month treatment (15).
A study was done in which letrozole was prescribed for 
ten post-menopausal women with endometrial cancer. 
Generally, in the first stage, about fourteen days before 
surgery, the final result confirmed positive clinical change 
of letrozole (16).
In this study, the case-study group consisted of 
post-menopausal women, and the duration of treatment 
with letrozole was short. However, a positive effect was 
recorded in this study. All these studies show that the du-
ration of treatment with letrozole affects the level of en-
dometrial thickness reduction. The aromatase inhibitor 
(letrozole and anastrozole) inhibits the aromatization of 
endogen into estrogen peripherally (7,17).
There was no significant relationship between the 2 
groups during 2, 3 and 6 months after the beginning of 
treatment in terms of the level of menstruation, but there 
was a significant difference before and after treatment. 
Although the level of estradiol in serum was significant-
ly reduced, there was no significant relationship between 
the 2 groups from the level of endometrial thickness re-
duction standpoint, and both had a rather equal decrease 
in the amount of thickness. One the important criteria in 
IVF cycle are endometrial thickness (18-23).
Conclusion
This study shows that letrozole can be used to treat pa-
tients with simple hyperplasia, who cannot undergo treat-
ment with medroxyprogesterone or are sensitive towards 
this drug by producing some complications (like mood 
changes, vascular and metabolic changes).
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